investigational new drug

Repligen soon will begin a first-ever human trial of a drug created specifically for spinal muscular atrophy;  FDA grants fast track designation

posted on May 20, 2011 - 11:13am
In a historic first, biotech company Repligen Corp., of Waltham, Mass., has received approval from the U.S. Food and Drug Administration (FDA) to begin a phase 1 clinical trial of the experimental drug RG3039 for spinal muscular atrophy (SMA).

New strategies are positioning MDA's research program for success

posted on January 1, 2008 - 3:06pm
QUEST Vol. 15, No. 1
The fast pace of scientific progress in this first decade of the 21st century, coupled with expanding knowledge about human genetics and disease, has led to significant changes in the way MDA approaches research.